Table 1.
The outpatient utilization of antibacterial drugs for systemic use (ATC group J01), expressed in DIDs with growth index (GI).
| 2018 | 2019 | GI 19/18 * | 2020 | GI 20/19 ** | |
|---|---|---|---|---|---|
| III level of the ATC classification | |||||
| J01C (beta-lactam antibiotics) | 15.17 | 10.61 | −30.06% | 17.12 | 61.31% |
| J01D (other beta-lactam antibiotics) | 2.85 | 2.68 | −5.96% | 5.93 | 121.40% |
| J01F (macrolides, lincosamides, and streptogramines) | 2.15 | 2.23 | 3.72% | 3.48 | 55.85% |
| J01M (quinolones) | 2.23 | 2.05 | −8.07% | 2.22 | 8.49% |
| J01A (tetracyclines) | 1.71 | 1.15 | −32.75% | 1.13 | −2.31% |
| J01E (sulfonamides and trimethoprim) | 1.01 | 1.04 | 2.97% | 0.86 | −16.80% |
| J01X (other antibiotics) | 0.43 | 0.36 | −17.13% | ||
| J01G (aminoglycosides) | 0.05 | 0.05 | 0.00% | 0.04 | −24.31% |
| IV level of the ATC classification | |||||
| J01DB (first-generation cephalosporins) | 1.84 | 1.59 | −13.59% | 4.77 | 200% |
| J01DC (second-generation cephalosporins) | 0.72 | 0.61 | −15.28% | 0.52 | −14.75% |
| J01DD (third-generation cephalosporins) | 0.29 | 0.46 | 58.62% | 0.63 | 36.96% |
| J01DE (fourth-generation cephalosporins | 0 | 0.000178 | 1.81 × 10−5 | −89.83% | |
| J01FA (macrolides) | 2.06 | 2.14 | 3.88% | 3.41 | 59.34% |
| J01FF (lincosamides) | 0.08 | 0.09 | 12.50% | 0.07 | −22.22% |
| J01MA (fluoroquinolones) | 2.11 | 1.99 | −5.69% | 2.22 | 11.56% |
| J01MB (other quinolones) | 0.13 | 0.05 | −61.54% | 4.82 × 10−5 | −99.90% |
| V level of the ATC classification | |||||
| J01CA04 (amoxicillin) | 11.08 | 6.6 | −40.43% | 13.21 | 100.08% |
| J01DB01 (cephalexin) | 1.84 | 1.6 | −13.04% | 4.77 | 198.44% |
| J01CR02 (amoxicillin/clavulanic acid) | 3.04 | 2.99 | −1.64% | 3.24 | 8.32% |
| J01FA10 (azithromycin) | 1.14 | 1.28 | 12.28% | 2.79 | 117.43% |
| J01MA02 (ciprofloxacin) | 1.52 | 1.45 | −4.60% | 1.33 | −8.76% |
| J01AA02 (doxycycline) | 1.45 | 1.15 | −20.69% | 1.13 | −1.83% |
| J01EE01 (sulfamethoxazole, trimethoprim) | 1.01 | 1.04 | 2.97% | 0.86 | −16.80% |
| J01MA12 (levofloxacin) | 0.33 | 0.32 | −3.03% | 0.65 | 101.58% |
| J01CE02 (phenoxymethylpenicillin) | 0.9 | 0.84 | −6.67% | 0.55 | −34.31% |
| J01DC02 (cefuroxime) | 0.68 | 0.58 | −14.71% | 0.51 | −12.90% |
| J01FA09 (clarithromycin) | 0.49 | 0.49 | 0.00% | 0.41 | −17.35% |
| J01DD08 (cefixime) | 0.19 | 0.24 | 26.31% | 0.38 | 60.02% |
| J01DD04 (ceftriaxone) | 0.07 | 0.18 | 157.14% | 0.2 | 9.19% |
| J01FA01 (erythromycin) | 0.42 | 0.34 | −19.05% | 0.19 | −42.56% |
| J01MA06 (norfloxacin) | 0.21 | 0.19 | −9.52% | 0.17 | −11.51% |
| J01CA01 (ampicillin) | 0.12 | 0.15 | 25.00% | 0.09 | −36.97% |
| J01MA14 (moxifloxacin) | 0.03 | 0.04 | 33.33% | 0.08 | 124.60% |
| J01DD13 (cefpodoxime) | 0.02 | 0.04 | 100.00% | 0.05 | 21.39% |
* GI 19/18—growth index that represents the change in antibiotic utilization in 2019 versus 2018. ** GI 20/19—growth index that represents the change in antibiotic utilization in 2020 versus 2019.